An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007636/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
To assess the overall safety of lixisenatide once daily treatment in monotherapy over 24 and
52 weeks in patients with type 2 diabetes in Japan
Secondary Objective:
To assess the effects of lixisenatide once daily treatment in monotherapy over 24 and 52
weeks on:
- HbA1c (Glycated hemoglobin A1c) reduction;
- Fasting plasma glucose;
- Body weight.
提供机构：
Vivli
创建时间：
2022-02-02
